Masanori Inoue
YOU?
Author Swipe
View article: Case Report: Zinc deficiency as a modifiable risk factor for enfortumab vedotin–induced cutaneous adverse events
Case Report: Zinc deficiency as a modifiable risk factor for enfortumab vedotin–induced cutaneous adverse events Open
Background Enfortumab vedotin (EV) is effective for advanced urothelial carcinoma, but cutaneous adverse events (CAEs) remain a major barrier to treatment continuity. Intertriginous eruptions resembling symmetrical drug-related intertrigin…
View article: Is Pain Intensity Related to Psychosocial Factors in Chronic Non‐Nociceptive Orofacial Pain Patients?
Is Pain Intensity Related to Psychosocial Factors in Chronic Non‐Nociceptive Orofacial Pain Patients? Open
Background In order to understand the psychological aspects of chronic pain, it is important to consider the relationships between pain and psychosocial factors in patients with chronic pain. While psychosocial factors are known to affect …
View article: Disease Complexity and Nodule-Specific Responses to Atezolizumab plus Bevacizumab in Advanced Hepatocellular Carcinoma
Disease Complexity and Nodule-Specific Responses to Atezolizumab plus Bevacizumab in Advanced Hepatocellular Carcinoma Open
Background: Advanced hepatocellular carcinoma (HCC) presents a range of presentations and responses to immunotherapy. We sought to determine the effects of Atez/Bev in patients with advanced HCC and various prognostic factors. Methods: We …
View article: Randomized phase II study comparing two doses of regorafenib in second-line treatment for advanced hepatocellular carcinoma
Randomized phase II study comparing two doses of regorafenib in second-line treatment for advanced hepatocellular carcinoma Open
jRCTs031190103.
View article: Patients With Hereditary Hemorrhagic Telangiectasia Diagnosed by Nanopore Long Read Sequencer
Patients With Hereditary Hemorrhagic Telangiectasia Diagnosed by Nanopore Long Read Sequencer Open
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disorder characterized by excessive and frequent epistaxis, telangiectasia, and visceral involvement, with a strong positive family history. The genes responsible for HHT…
View article: Diagnosis and Treatment of Postoperative Hepatic Lymphorrhea
Diagnosis and Treatment of Postoperative Hepatic Lymphorrhea Open
Postoperative hepatic lymphorrhea is a rare complication that can lead to refractory ascites. During surgery with lymph node dissection of the hepatoduodenal ligament, leakage of liver lymph into the abdominal cavity can occur. Due to the …
View article: Assessment of Single Photon Emission Computed Tomography 123I-IMP Brain Scan Parameters Using Low Energy High Resolution Collimator and 3D Iterative Image Reconstruction Algorithm (Flash 3D)
Assessment of Single Photon Emission Computed Tomography 123I-IMP Brain Scan Parameters Using Low Energy High Resolution Collimator and 3D Iterative Image Reconstruction Algorithm (Flash 3D) Open
Objective Statistical parametric mapping of 123I-IMP brain SPECT images has been used for brain disorders such as Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB) for several decade. The analysis results highly depen…
View article: Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study)
Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study) Open
Summary This study aimed to complement the results of the REACH-2 study by prospectively evaluating the safety and efficacy of ramucirumab in advanced hepatocellular carcinoma (HCC) in a real-world setting. This was an open-label, nonrando…
View article: Assessment of Macrovascular Invasion in Advanced Hepatocellular Carcinoma: Clinical Implications and Treatment Outcomes with Systemic Therapy
Assessment of Macrovascular Invasion in Advanced Hepatocellular Carcinoma: Clinical Implications and Treatment Outcomes with Systemic Therapy Open
Introduction: Macrovascular invasion (MVI) is a strong prognostic factor for advanced hepatocellular carcinoma (HCC). The current criteria for radiological assessment are unclear in evaluating the impact of MVI on systemic th…
View article: Multiple asynchronous recurrence as a predictive factor for refractoriness against locoregional and surgical therapy in patients with intermediate-stage hepatocellular carcinoma
Multiple asynchronous recurrence as a predictive factor for refractoriness against locoregional and surgical therapy in patients with intermediate-stage hepatocellular carcinoma Open
View article: Clinical risk factors for portal hypertension-related complications in systemic therapy for hepatocellular carcinoma
Clinical risk factors for portal hypertension-related complications in systemic therapy for hepatocellular carcinoma Open
View article: Ramucirumab for advanced hepatocellular carcinoma in the current real world: A Japanese single-arm study post-REACH-2 (The R-evolution Study)
Ramucirumab for advanced hepatocellular carcinoma in the current real world: A Japanese single-arm study post-REACH-2 (The R-evolution Study) Open
Background This study aimed to complement the results of the REACH-2 study by prospectively evaluating the safety and efficacy of ramucirumab in advanced hepatocellular carcinoma (HCC) in a real-world setting. Methods This was an open-labe…
View article: Table S4 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study
Table S4 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study Open
Radiological assessments according to RECIST 1.1 (evaluation by each investigator)
View article: Table S8 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study
Table S8 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study Open
Correlations between plasma concentration and relative dose intensity of lenvatinib
View article: Figure S1 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study
Figure S1 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study Open
Patient flow of the LAUNCH study
View article: Table S4 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study
Table S4 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study Open
Radiological assessments according to RECIST 1.1 (evaluation by each investigator)
View article: Figure S3 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study
Figure S3 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study Open
Correlation of Child–Pugh score at baseline and at end of lenvatinib treatment
View article: Figure S1 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study
Figure S1 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study Open
Patient flow of the LAUNCH study
View article: Table S5 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study
Table S5 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study Open
Radiological assessments according to both mRECIST and RECIST 1.1 (evaluation by central review)
View article: Figure S2 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study
Figure S2 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study Open
Response to lenvatinib in 57 patients for efficacy analysis (evaluation by each investigator)
View article: Table S7 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study
Table S7 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study Open
Correlations between relative dose intensity and clinical outcomes of lenvatinib treatment
View article: Figure S4 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study
Figure S4 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study Open
Transition of RDI of lenvatinib during treatment
View article: Table S3 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study
Table S3 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study Open
Cause of dose modifications and treatment discontinuations due to adverse events
View article: Table S5 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study
Table S5 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study Open
Radiological assessments according to both mRECIST and RECIST 1.1 (evaluation by central review)
View article: Table S8 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study
Table S8 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study Open
Correlations between plasma concentration and relative dose intensity of lenvatinib
View article: Figure S6 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study
Figure S6 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study Open
Association between portal hypertension and relative dose intensity of lenvatinib
View article: Figure S5 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study
Figure S5 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study Open
Relationship between plasma concentration levels and lenvatinib dose modification
View article: Figure S2 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study
Figure S2 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study Open
Response to lenvatinib in 57 patients for efficacy analysis (evaluation by each investigator)
View article: Figure S3 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study
Figure S3 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study Open
Correlation of Child–Pugh score at baseline and at end of lenvatinib treatment
View article: Table S3 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study
Table S3 from A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study Open
Cause of dose modifications and treatment discontinuations due to adverse events